VCNX
Income statement / Annual
Last year (2024), Vaccinex, Inc.'s total revenue was $601.00 K,
an increase of 5.44% from the previous year.
In 2024, Vaccinex, Inc.'s net income was -$18.63 M.
See Vaccinex, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
Operating Revenue |
$601.00 K |
$570.00 K |
$100.00 K |
$900.00 K |
$50.00 K |
$523.00 K |
$724.00 K |
$90.00 K |
$316.00 K |
Cost of Revenue |
$0.00
|
$0.00
|
$207.00 K
|
$169.00 K
|
$2.00 K
|
$199.00 K
|
$1.03 M
|
$160.00 K
|
$115.00 K
|
Gross Profit |
$601.00 K
|
$570.00 K
|
-$107.00 K
|
$731.00 K
|
$48.00 K
|
$324.00 K
|
-$309.00 K
|
-$70.00 K
|
$201.00 K
|
Gross Profit Ratio |
1
|
1
|
-1.07
|
0.81
|
0.96
|
0.62
|
-0.43
|
-0.78
|
0.64
|
Research and Development Expenses |
$12.55 M
|
$16.57 M
|
$13.98 M
|
$17.16 M
|
$21.55 M
|
$25.67 M
|
$22.35 M
|
$16.55 M
|
$16.03 M
|
General & Administrative Expenses |
$6.79 M
|
$6.88 M
|
$6.20 M
|
$6.23 M
|
$7.41 M
|
$6.67 M
|
$4.62 M
|
$4.48 M
|
$4.43 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$6.79 M
|
$6.88 M
|
$6.20 M
|
$6.23 M
|
$7.41 M
|
$6.67 M
|
$4.62 M
|
$4.48 M
|
$4.43 M
|
Other Expenses |
$0.00
|
$0.00
|
-$175.00 K
|
$43.00 K
|
-$575.00 K
|
$152.00 K
|
$165.00 K
|
-$40.00 K
|
-$4.00 K
|
Operating Expenses |
$19.34 M
|
$23.46 M
|
$20.01 M
|
$23.39 M
|
$28.38 M
|
$32.34 M
|
$26.97 M
|
$21.03 M
|
$20.46 M
|
Cost And Expenses |
$19.34 M
|
$23.46 M
|
$20.01 M
|
$23.39 M
|
$28.38 M
|
$32.54 M
|
$28.01 M
|
$21.19 M
|
$20.58 M
|
Interest Income |
$0.00
|
$0.00
|
$2.00 K
|
$809.00 K
|
$489.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$2.00 K
|
$1.00 K
|
$2.00 K
|
$809.00 K
|
$489.00 K
|
$0.00
|
$392.00 K
|
$1.36 M
|
$2.99 M
|
Depreciation & Amortization |
$94.00 K
|
$119.00 K
|
$207.00 K
|
$169.00 K
|
$307.00 K
|
$249.00 K
|
$223.00 K
|
$206.00 K
|
$178.00 K
|
EBITDA |
-$18.54 M |
-$19.75 M |
-$19.61 M |
-$21.40 M |
-$28.06 M |
-$31.61 M |
-$28.90 M |
-$17.20 M |
-$10.78 M |
EBITDA Ratio |
-30.85
|
-34.65
|
-196.06
|
-23.78
|
-561.1
|
-60.45
|
-39.92
|
-191.06
|
-34.1
|
Operating Income Ratio |
-31.17
|
-40.15
|
-199.06
|
-24.99
|
-566.62
|
-61.21
|
-37.68
|
-234.49
|
-64.11
|
Total Other Income/Expenses Net |
$101.00 K
|
$2.63 M
|
$91.00 K
|
$110.00 K
|
-$520.00 K
|
$152.00 K
|
-$2.24 M
|
$2.35 M
|
$6.32 M
|
Income Before Tax |
-$18.63 M
|
-$20.25 M
|
-$19.82 M
|
-$22.38 M
|
-$28.85 M
|
-$31.86 M
|
-$29.52 M
|
-$18.76 M
|
-$13.94 M
|
Income Before Tax Ratio |
-31
|
-35.53
|
-198.15
|
-24.87
|
-577.02
|
-60.92
|
-40.77
|
-208.43
|
-44.12
|
Income Tax Expense |
$0.00
|
$0.00
|
-$93.00 K
|
$852.00 K
|
$458.00 K
|
$152.00 K
|
-$1.85 M
|
$1.28 M
|
$2.99 M
|
Net Income |
-$18.63 M
|
-$20.25 M
|
-$19.72 M
|
-$23.23 M
|
-$29.31 M
|
-$32.02 M
|
-$29.52 M
|
-$18.72 M
|
-$13.94 M
|
Net Income Ratio |
-31
|
-35.53
|
-197.22
|
-25.81
|
-586.18
|
-61.21
|
-40.77
|
-208.02
|
-44.12
|
EPS |
-8.88 |
-43.68 |
-97.59 |
-170.04 |
-327.62 |
-521.95 |
-1186.7 |
-689.86 |
-526.85 |
EPS Diluted |
-8.88 |
-43.68 |
-97.59 |
-169.11 |
-327.62 |
-521.95 |
-1186.7 |
-689.86 |
-526.85 |
Weighted Average Shares Out |
$2.10 M
|
$463.65 K
|
$202.08 K
|
$136.63 K
|
$89.46 K
|
$61.34 K
|
$24.87 K
|
$27.14 K
|
$26.47 K
|
Weighted Average Shares Out Diluted |
$2.10 M
|
$463.65 K
|
$202.08 K
|
$137.38 K
|
$89.46 K
|
$61.34 K
|
$24.87 K
|
$27.14 K
|
$26.47 K
|
Link |
|
|
|
|
|
|
|
|
|